← Oncology Approval Tracker

FDA DECISION ·

Iclusig

ponatinib · Takeda Pharmaceuticals

Accelerated approvalNew or expanded indicationAcute lymphoblastic leukemia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia; use in combination with chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The label moved ponatinib into initial treatment, with molecular residual disease response supporting accelerated approval.

What research teams should watch

Set up consistent molecular sampling and track cardiovascular assessment and any response-guided dosing changes.

PRIMARY RECORDS

Sources